ChemLex, a Singapore-based AI company serving the pharmaceutical and biotech sectors, announced a $45 million funding round led by Granite Asia. The company works to shorten the drug discovery-to-delivery cycle while reducing energy consumption and waste.
ChemLex’s solution combines data-driven retrosynthesis prediction with real-time feedback and automated high-throughput experimentation. Its platform leverages proprietary AI algorithms and robotic systems capable of continuously designing, synthesizing and analyzing molecules to help companies shorten discovery times.
“We’re building an R&D engine that significantly accelerates organic synthesis, transforming both the speed and efficiency of drug discovery,” Sean Lin, ChemLex’s founder and CEO, said in a statement. “Singapore strengthens this effort and provides us an ecosystem to scale rapidly and support partners globally who need this capability now.”
Following its $26 million Series A round, this latest investment will help ChemLex accelerate the development of its AI-powered chemical synthesis system. The company has also signed a memorandum of understanding with Singapore’s Experimental Drug Development Centre to collaborate on small-molecule drug discovery solutions through advanced automation.
